node_label,participant_count,node_type,study_phase
"Patients screened for eligibility",485,start,screening
"Met inclusion criteria",412,process,screening
"Provided informed consent",389,process,enrollment
"Randomized to treatment",350,decision,randomization
"Assigned to Drug A",175,allocation,treatment
"Assigned to Drug B",175,allocation,treatment
"Completed treatment - Drug A",156,outcome,completion
"Completed treatment - Drug B",162,outcome,completion
"Included in primary analysis",318,final,analysis
"Included in safety analysis",340,final,analysis
"Lost to follow-up",32,exclusion,dropout
"Withdrew consent",21,exclusion,dropout
"Adverse events leading to discontinuation",19,exclusion,safety